Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
GEN-1184 by Genmab for Fallopian Tube Cancer: Likelihood of Approval
GEN-1184 is under clinical development by Genmab and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase...
GEN-1184 by Genmab for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
GEN-1184 is under clinical development by Genmab and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...
GEN-1184 by Genmab for Malignant Mesothelioma: Likelihood of Approval
GEN-1184 is under clinical development by Genmab and currently in Phase II for Malignant Mesothelioma. According to GlobalData, Phase II...
GEN-1184 by Genmab for Non-Small Cell Lung Cancer: Likelihood of Approval
GEN-1184 is under clinical development by Genmab and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
GEN-1184 by Genmab for Epithelial Ovarian Cancer: Likelihood of Approval
GEN-1184 is under clinical development by Genmab and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData, Phase...
GEN-1184 by Genmab for Peritoneal Cancer: Likelihood of Approval
GEN-1184 is under clinical development by Genmab and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II...
Risk adjusted net present value: What is the current valuation of Genmab's GEN-1184?
GEN-1184 is a monoclonal antibody conjugated commercialized by Genmab, with a leading Phase II program in Epithelial Ovarian Cancer. According...